Pharma News Briefs

• Barr Labs announced Monday that it has amended its paragraph IV certification with respect to Lilly's Zyprexa Zydis patent to a paragraph III certification, and that Lilly has dropped its related patent suit against Barr.  See also this AP article.
• FDA Law Blog had this post Tuesday about yet another new study on authorized generics.
• Patently-O reported today that the district court overseeing Abbott's Biaxin XL litigation against Sandoz has denied Sandoz's motion to stay a preliminary injunction pending appeal.  For background, see this April OBB post.
• The Patent Prospector recently posted Hal Wegner's new paper on post-KSR chemical obviousness.